H3-3B
Basic information
Region (hg38): 17:75776434-75785893
Previous symbols: [ "H3F3B" ]
Links
Phenotypes
GenCC
Source:
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Bryant-Li-Bhoj neurodevelopmental syndrome 2 | AD | Audiologic/Otolaryngologic | Early recognition and treatment of hearing impairment may improve outcomes, including speech and language development | Audiologic/Otolaryngologic; Craniofacial; Musculoskeletal; Neurologic; Ophthalmologic | 33268356; 34876591 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (2 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the H3-3B gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 1 | |||||
missense | 12 | |||||
nonsense | 0 | |||||
start loss | 1 | |||||
frameshift | 0 | |||||
inframe indel | 1 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 2 | |||||
Total | 2 | 7 | 6 | 0 | 2 |
Variants in H3-3B
This is a list of pathogenic ClinVar variants found in the H3-3B region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
17-75776919-C-T | Benign (Jul 13, 2018) | |||
17-75778594-CTT-C | Intellectual disability;Brain imaging abnormality;Delayed speech and language development;Short stature;Global developmental delay | Likely pathogenic (Jul 15, 2021) | ||
17-75778629-T-C | Bryant-Li-Bhoj neurodevelopmental syndrome 2 • H3-3B-related disorder | Pathogenic/Likely pathogenic (Jun 26, 2023) | ||
17-75778630-G-T | Bryant-Li-Bhoj neurodevelopmental syndrome 2 | Likely pathogenic (May 22, 2023) | ||
17-75778641-G-C | Bryant-Li-Bhoj neurodevelopmental syndrome 2 | Pathogenic (Feb 02, 2022) | ||
17-75778652-G-T | Hemiparkinsonism-hemiatrophy syndrome | Uncertain significance (Nov 16, 2020) | ||
17-75778662-G-A | Uncertain significance (Jan 04, 2024) | |||
17-75778678-G-C | Bryant-Li-Bhoj neurodevelopmental syndrome 2 | Uncertain significance (Sep 28, 2023) | ||
17-75778796-G-A | Benign (Sep 04, 2019) | |||
17-75778883-C-T | Uncertain significance (Oct 18, 2021) | |||
17-75778937-A-T | Intellectual disability;Brain imaging abnormality;Delayed speech and language development;Short stature;Global developmental delay • Bryant-Li-Bhoj neurodevelopmental syndrome 2 | Pathogenic/Likely pathogenic (Feb 02, 2022) | ||
17-75779056-T-C | Inborn genetic diseases | Conflicting classifications of pathogenicity (Nov 25, 2024) | ||
17-75779072-C-T | Neurodevelopmental disorder | Pathogenic/Likely pathogenic (Apr 18, 2022) | ||
17-75779077-G-A | Likely pathogenic (May 01, 2023) | |||
17-75779084-G-A | Bryant-Li-Bhoj neurodevelopmental syndrome 2 | Likely pathogenic (Oct 16, 2024) | ||
17-75779084-GAGCGCTTTTCCT-G | Uncertain significance (Sep 09, 2022) | |||
17-75779087-C-G | Bryant-Li-Bhoj neurodevelopmental syndrome 2 | Pathogenic (Feb 02, 2022) | ||
17-75779107-G-C | Bryant-Li-Bhoj neurodevelopmental syndrome 2 | Likely pathogenic (Jan 31, 2023) | ||
17-75779107-G-T | Intellectual disability;Brain imaging abnormality;Delayed speech and language development;Short stature;Global developmental delay | Likely pathogenic (Jul 15, 2021) | ||
17-75779123-G-A | Bryant-Li-Bhoj neurodevelopmental syndrome 2 | Likely pathogenic (Nov 27, 2023) | ||
17-75779125-G-T | Bryant-Li-Bhoj neurodevelopmental syndrome 2 | Uncertain significance (Jul 17, 2023) | ||
17-75779138-C-T | Likely pathogenic (Jul 06, 2021) | |||
17-75779140-G-A | Bryant-Li-Bhoj neurodevelopmental syndrome 2 | Likely pathogenic (Sep 01, 2022) | ||
17-75779144-A-G | Pathogenic (Jul 15, 2022) | |||
17-75779147-T-C | Intellectual disability;Brain imaging abnormality;Delayed speech and language development;Short stature;Global developmental delay | Likely pathogenic (Jul 15, 2021) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
H3-3B | protein_coding | protein_coding | ENST00000254810 | 3 | 9460 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.807 | 0.189 | 0 | 0 | 0 | 0 | 0.00 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 2.88 | 8 | 80.8 | 0.0990 | 0.00000363 | 862 |
Missense in Polyphen | 1 | 14.871 | 0.067244 | 190 | ||
Synonymous | -7.71 | 89 | 32.8 | 2.71 | 0.00000150 | 295 |
Loss of Function | 2.16 | 0 | 5.44 | 0.00 | 2.37e-7 | 62 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.00 | 0.00 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Variant histone H3 which replaces conventional H3 in a wide range of nucleosomes in active genes. Constitutes the predominant form of histone H3 in non-dividing cells and is incorporated into chromatin independently of DNA synthesis. Deposited at sites of nucleosomal displacement throughout transcribed genes, suggesting that it represents an epigenetic imprint of transcriptionally active chromatin. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling. {ECO:0000269|PubMed:14718166, ECO:0000269|PubMed:15776021, ECO:0000269|PubMed:16258499}.;
- Disease
- DISEASE: Glioma (GLM) [MIM:137800]: Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. {ECO:0000269|PubMed:22286061, ECO:0000269|PubMed:22286216, ECO:0000269|PubMed:23539269}. Note=The gene represented in this entry is involved in disease pathogenesis. H3F3A mutations affecting residues involved in post-translational modifications of histone H3.3 are recurrent in malignant, aggressive gliomas including glioblastoma multiforme (GBM) and diffuse intrinsic pontine glioma (DIPG) (PubMed:22286061, PubMed:22286216). The mechanism through which mutations lead to tumorigenesis involves altered histones methylation, impaired regulation of Polycomb repressive complex 2 (PRC2) activity, and aberrant epigenetic regulation of gene expression (PubMed:23539269, PubMed:23539183, PubMed:23603901). {ECO:0000269|PubMed:22286061, ECO:0000269|PubMed:22286216, ECO:0000269|PubMed:23539183, ECO:0000269|PubMed:23539269, ECO:0000269|PubMed:23603901}.; DISEASE: Note=H3F3A and H3F3B mutations affecting residues involved in post-translational modifications of histone H3.3 are implicated in the pathogenesis of some bone and cartilage neoplasms. Mutations have been found with high prevalence in chondroblastoma and giant cell tumors of bone, and with low frequency in osteosarcoma, conventional chondrosarcoma and clear cell chondrosarcoma. Chondroblastoma samples frequently carry a H3F3B mutation affecting residue Lys-37 (H3K36), although H3F3A is mutated in some cases. Most giant cell tumors of bone harbor H3F3A mutations affecting residue Gly-35 (H3G34). {ECO:0000269|PubMed:24162739}.;
- Pathway
- Systemic lupus erythematosus - Homo sapiens (human);Transcriptional misregulation in cancer - Homo sapiens (human);Alcoholism - Homo sapiens (human);Histone Modifications;Tumor suppressor activity of SMARCB1;B-WICH complex positively regulates rRNA expression;ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression;Positive epigenetic regulation of rRNA expression;SIRT1 negatively regulates rRNA expression;NoRC negatively regulates rRNA expression;Negative epigenetic regulation of rRNA expression;Signaling by WNT;Signal Transduction;DNA methylation;Epigenetic regulation of gene expression;Gene expression (Transcription);the prc2 complex sets long-term gene silencing through modification of histone tails;p38 mapk signaling pathway;Generic Transcription Pathway;Oxidative Stress Induced Senescence;Senescence-Associated Secretory Phenotype (SASP);Cellular Senescence;Factors involved in megakaryocyte development and platelet production;Cellular responses to stress;Metabolism of proteins;Reproduction;RNA Polymerase I Promoter Clearance;RNA Polymerase I Promoter Opening;RNA Polymerase II Transcription;RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function;RNA Polymerase I Transcription;Amyloid fiber formation;RNA Polymerase I Chain Elongation;akap95 role in mitosis and chromosome dynamics;Meiotic recombination;Meiosis;Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3;RHO GTPases activate PKNs;Cellular responses to external stimuli;RHO GTPase Effectors;Signaling by Rho GTPases;Hemostasis;Condensation of Prophase Chromosomes;Signaling by Nuclear Receptors;Mitotic Prophase;M Phase;Estrogen-dependent gene expression;Transcriptional regulation by small RNAs;RUNX1 regulates transcription of genes involved in differentiation of HSCs;Cell Cycle;Cell Cycle, Mitotic;ESR-mediated signaling;Aurora C signaling;Transcriptional regulation by RUNX1;Aurora B signaling;Formation of the beta-catenin:TCF transactivating complex;TCF dependent signaling in response to WNT;Gene Silencing by RNA;PRC2 methylates histones and DNA
(Consensus)
Intolerance Scores
- loftool
- rvis_EVS
- -0.21
- rvis_percentile_EVS
- 38.28
Haploinsufficiency Scores
- pHI
- 0.298
- hipred
- Y
- hipred_score
- 0.752
- ghis
- 0.501
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.997
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- H3f3b
- Phenotype
- growth/size/body region phenotype; cellular phenotype; reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; embryo phenotype;